Evidence map›Paper›PMID 28006972›Full record

ArticleAIDS care2017

Identifying HIV care enrollees at-risk for cannabis use disorder.

Bryan Hartzler, Beatriz H Carlini, Howard Newville, Heidi M Crane, Joseph J Eron, Elvin H Geng, W Christopher Mathews, Kenneth H Mayer, Richard D Moore, Michael J Mugavero and 3 more

Abstract read
In one paragraph

Article in AIDS care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Neuroimaging the Neuropathogenesis of HIV.Current HIV/AIDS reports · 2021
    Review
  10. Synergistic effects of HIV and marijuana use on functional brain network organization.Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Article
  11. Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Bryan Hartzlera Alcohol & Drug Abuse Institute , University of Washington , Seattle , WA , USA.
Beatriz H Carlinia Alcohol & Drug Abuse Institute , University of Washington , Seattle , WA , USA.
Howard Newvillea Alcohol & Drug Abuse Institute , University of Washington , Seattle , WA , USA.
Heidi M Craneb Division of Allergy and Infectious Disease , University of Washington , Seattle , WA , USA.
Joseph J Eronc Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
Elvin H Genge School of Medicine , University of California , San Francisco , CA , USA.
W Christopher Mathewsf Department of Medicine , University of California , San Diego , CA , USA.
Kenneth H Mayerg School of Medicine , Harvard University , Boston , MA , USA.
Richard D Moorej Department of Medicine , Johns Hopkins University , Baltimore , MD , USA.
Michael J Mugaverom Department of Medicine , University of Alabama , Birmingham , AL , USA.
Sonia Napravnikc Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
Benigno Rodriguezn Department of Medicine , Case Western Reserve University , Cleveland , OH , USA.
Dennis M Donovana Alcohol & Drug Abuse Institute , University of Washington , Seattle , WA , USA.
Seattle Indian Health Board · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · USCase Western Reserve University · USCenter for Global Health · USFenway Health · USUniversity of Alabama at Birmingham · USUniversity of California, San Diego · USUniversity of California, San Francisco · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Informing Dissemination of Behavior Therapies to Enhance HIV Care Among Substance AbusersR03DA039719 · NIDA · UNIVERSITY OF WASHINGTON · PI HARTZLER, BRYAN J · 2015 to 2016
$249k
NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI067039NIDA NIH HHS R03 DA039719NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

Increased scientific attention given to cannabis in the United States has particular relevance for its domestic HIV care population, given that evidence exists for both cannabis as a therapeutic agent and cannabis use disorder (CUD) as a barrier to antiretroviral medication adherence. It is critical to identify relative risk for CUD among demographic subgroups of HIV patients, as this will inform detection and intervention efforts. A Center For AIDS Research Network of Integrated Clinical Systems cohort (N = 10,652) of HIV-positive adults linked to care at seven United State sites was examined for this purpose. Based on a patient-report instrument with validated diagnostic threshold for CUD, the prevalence of recent cannabis use and corresponding conditional probabilities for CUD were calculated for the aggregate sample and demographic subgroups. Generalized estimating equations then tested models directly examining patient demographic indices as predictors of CUD, while controlling for history and geography. Conditional probability of CUD among cannabis-using patients was 49%, with the highest conditional probabilities among demographic subgroups of young adults and those with non-specified sexual orientation (67-69%) and the lowest conditional probability among females and those 50+ years of age (42% apiece). Similarly, youthful age and male gender emerged as robust multivariate model predictors of CUD. In the context of increasingly lenient policies for use of cannabis as a therapeutic agent for chronic conditions like HIV/AIDS, current study findings offer needed direction in terms of specifying targeted patient groups in HIV care on whom resources for enhanced surveillance and intervention efforts will be most impactful.

Indexed as

CannabisAdolescentAdultCohort StudiesFemaleHIV InfectionsHumansMaleMarijuana AbuseMarijuana SmokingMedication AdherenceMiddle AgedPrevalenceUnited StatesYoung AdultCannabis use disordercare settingsHIV/AIDSUnited States

Identifiers

PMID28006972
PMCPMC5573588
OpenAlexW2562097331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.